Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287063 · ClinicalTrials.gov registry record
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- 6
- Enrollment target
NCT03287063 is a clinical trial that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT03287063 was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to assess initial GBM heterogeneity by performing histological and genomic analysis of biopsies targeted by advanced MRI before treatment.
Interventions
- OTHER Tumor Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2020-03-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287063
The ClinicalTrials.gov registry entry for NCT03287063 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tumor Biopsy is the first listed.
NCT03287063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03287063 about?
NCT03287063 is a clinical study titled "Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma". Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive tumor resistance pathways. The researchers propose a unique approach to ass...
What is the current status of trial NCT03287063?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2018-07-05. Estimated completion is 2020-03-23.
What interventions are being tested in trial NCT03287063?
The interventions under investigation include: Tumor Biopsy (OTHER).
Who is sponsoring clinical trial NCT03287063?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.